When mutants gain new powers: news from the mutant p53 field

Ran Brosh; Varda Rotter

doi:10.1038/nrc2693

Mutant p53 proteins not only lose their tumour suppressive ability, but also gain new properties that promote tumorigenesis. What are these properties and what are the clinical implications?

Loading next page...

References (202)

G. Salvatore, T. Nappi, P. Salerno, Yuan Jiang, C. Garbi, C. Ugolini, P. Miccoli, F. Basolo, M. Castellone, A. Cirafici, R. Melillo, A. Fusco, M. Bittner, M. Santoro (2007)
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma.
Cancer research, 67 21
C. Como, C. Gaiddon, C. Prives (1999)
p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Molecular and Cellular Biology, 19
D. Lane, L. Crawford (1979)
T antigen is bound to a host protein in SY40-transformed cells
Nature, 278
H. Werner, E. Karnieli, F. Rauscher, D. Leroith (1996)
Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene.
Proceedings of the National Academy of Sciences of the United States of America, 93 16
T. Sørlie, C. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. Eisen, M. Rijn, S. Jeffrey, T. Thorsen, H. Quist, J. Matese, P. Brown, D. Botstein, P. Lønning, A. Børresen-Dale (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
Proceedings of the National Academy of Sciences of the United States of America, 98
F. Dicker, H. Herholz, S. Schnittger, A. Nakao, N. Patten, Lin Wu, W. Kern, T. Haferlach, C. Haferlach (2009)
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype
Leukemia, 23
Chao Lu, W. El-Deiry (2009)
Targeting p53 for enhanced radio- and chemo-sensitivity
Apoptosis, 14
A. Kamal, Lia Thao, J. Sensintaffar, Lin Zhang, M. Boehm, L. Fritz, F. Burrows (2003)
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Nature, 425
P. Lazarus, H. Garewal, J. Sciuuba, N. Zwiebel, A. Calcagnotto, A. Fair, S. Schaefer, J. Richie (1995)
A low incidence of p53 mutations in pre‐malignant lesions of the oral cavity from non‐tobacco users
International Journal of Cancer, 60
X Ma (2008)
TP53 and KRAS mutations as markers of outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer (NSCL): the International Adjuvant Lung Cancer Trial (IALT) biological program
Ann. Oncol. Abstr., 19
G. Qin, Jong Park, Sow‐Yeh Chen, P. Lazarus (1999)
A high prevalence of p53 mutations in pre‐malignant oral erythroplakia
International Journal of Cancer, 80
H. Usui, T. Otani (2001)
Detection of K-ras and p53 gene mutations in pancreatic juice for the diagnosis of intraductal papillary mucinous tumors.
Pancreas, 22 1
J. Alsner, V. Jensen, M. Kyndi, B. Offersen, P. Vu, A. Børresen-Dale, J. Overgaard (2008)
A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients
Acta Oncologica, 47
Gopal Dhar, S. Banerjee, Kakali Dhar, O. Tawfik, M. Mayo, P. Vanveldhuizen, S. Banerjee (2008)
Gain of oncogenic function of p53 mutants induces invasive phenotypes in human breast cancer cells by silencing CCN5/WISP-2.
Cancer research, 68 12
L. Weisz, M. Oren, V. Rotter (2007)
Transcription regulation by mutant p53
Oncogene, 26
Wensheng Yan, Gang Liu, A. Scoumanne, Xinbin Chen (2008)
Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.
Cancer research, 68 16
T. Soussi (2000)
p53 Antibodies in the sera of patients with various types of cancer: a review.
Cancer research, 60 7
Y. Barak, T. Juven, R. Haffner, M. Oren (1993)
mdm2 expression is induced by wild type p53 activity.
The EMBO Journal, 12
Jiayuh Lin, A. Teresky, Arnold Levine (1995)
Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants.
Oncogene, 10 12
S. Haupt, Silvia Agostino, I. Mizrahi, Osnat Alsheich-Bartok, M. Voorhoeve, A. Damalas, G. Blandino, Y. Haupt (2009)
Promyelocytic leukemia protein is required for gain of function by mutant p53.
Cancer research, 69 11
M. Hollstein, D. Sidransky, B. Vogelstein, C. Harris (1991)
p53 mutations in human cancers.
Science, 253 5015
M. Ryu, Y. Kang, S. Jang, T. Kim, H. Lee, J. Kim, Y. Park, S. Lee, B. Ryoo, H. Chang, J. Lee, J. Yook, B. Kim, J. Lee (2007)
Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours
Histopathology, 51
J. Milner, E. Medcalf, Alistair Cook (1991)
Tumor suppressor p53: analysis of wild-type and mutant p53 complexes
Molecular and Cellular Biology, 11
Amir Zalcenstein, L. Weisz, P. Stambolsky, J. Bar, V. Rotter, M. Oren (2006)
Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53
Oncogene, 25
J. Varley (2003)
Germline TP53 mutations and Li‐Fraumeni syndrome
Human Mutation, 21
D. Solit, N. Rosen (2006)
Hsp90: a novel target for cancer therapy.
Current topics in medicinal chemistry, 6 11
L. Nie, M. Sasaki, C. Maki (2007)
Regulation of p53 Nuclear Export through Sequential Changes in Conformation and Ubiquitination*
Journal of Biological Chemistry, 282
T Sjoblom (2006)
The consensus coding sequences of human breast and colorectal cancers
Science, 314
K. Young, K. Leroy, M. Møller, G. Colleoni, M. Sánchez-Beato, F. Kerbauy, C. Haioun, J. Eickhoff, A. Young, P. Gaulard, M. Piris, T. Oberley, W. Rehrauer, B. Kahl, J. Malter, E. Campo, J. Delabie, R. Gascoyne, A. Rosenwald, L. Rimsza, James Huang, R. Braziel, E. Jaffe, W. Wilson, L. Staudt, J. Vose, W. Chan, D. Weisenburger, T. Greiner (2006)
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
Blood, 112 8
K. Chin, K. Ueda, I. Pastan, M. Gottesman (1992)
Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.
Science, 255 5043
V. Rotter, O. Witte, R. Coffman, D. Baltimore (1980)
Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50
Journal of Virology, 36
F. Bartel, Juliane-Susanne Jung, A. Böhnke, E. Gradhand, K. Zeng, C. Thomssen, S. Hauptmann (2008)
Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival
Clinical Cancer Research, 14
F. Aguilar, Hussain Sp, P. Cerutti (1993)
Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes.
Proceedings of the National Academy of Sciences of the United States of America, 90 18
D. Bergamaschi, M. Gasco, L. Hiller, A. Sullivan, N. Syed, G. Trigiante, I. Yulug, M. Merlano, G. Numico, A. Comino, M. Attard, O. Reelfs, B. Gusterson, A. Bell, V. Heath, M. Tavassoli, P. Farrell, PaulR Smith, Xin Lu, T. Crook (2003)
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.
Cancer cell, 3 4
S. Ahrendt, S. Halachmi, J. Chow, Li Wu, N. Halachmi, Stephen Yang, S. Wehage, J. Jen, D. Sidransky (1999)
Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array.
Proceedings of the National Academy of Sciences of the United States of America, 96 13
J Milner (1991)
10.1128/MCB.11.1.12
Mol. Cell Biol., 11
T. Göhler, S. Jäger, G. Warnecke, H. Yasuda, Ella Kim, W. Deppert (2005)
Mutant p53 proteins bind DNA in a DNA structure-selective mode
Nucleic Acids Research, 33
G. Bossi, E. Lapi, S. Strano, C. Rinaldo, G. Blandino, A. Sacchi (2006)
Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression
Oncogene, 25
C. Imbriano, A. Gurtner, F. Cocchiarella, Silvia Agostino, V. Basile, M. Gostissa, M. Dobbelstein, G. Sal, G. Piaggio, R. Mantovani (2005)
Direct p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G2/M Promoters
Molecular and Cellular Biology, 25
K. Young, D. Weisenburger, B. Dave, Lynette Smith, W. Sanger, J. Iqbal, E. Campo, J. Delabie, R. Gascoyne, G. Ott, L. Rimsza, H. Müller-Hermelink, E. Jaffe, A. Rosenwald, L. Staudt, W. Chan, T. Greiner (2007)
Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.
Blood, 110 13
B. Iacopetta (2003)
TP53 mutation in colorectal cancer
Human Mutation, 21
Ajay Jain, K. Chin, A. Børresen-Dale, B. Erikstein, P. Lønning, R. Kaaresen, J. Gray (2001)
Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival
Proceedings of the National Academy of Sciences of the United States of America, 98
A. Potti, J. Nevins (2008)
Utilization of genomic signatures to direct use of primary chemotherapy.
Current opinion in genetics & development, 18 1
B. Vogelstein, D. Lane, A. Levine (2000)
Surfing the p53 network
Nature, 408
M. Olivier, A. Petitjean, V. Marcel, Aurélia Pétré, M. Mounawar, A. Plymoth, C. Fromentel, C. Fromentel, P. Hainaut (2009)
Recent advances in p53 research: an interdisciplinary perspective
Cancer Gene Therapy, 16
A. Sigal, V. Rotter (2000)
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Cancer research, 60 24
N. Lukashchuk, K. Vousden (2007)
Ubiquitination and Degradation of Mutant p53
Molecular and Cellular Biology, 27
M. DeYoung, L. Ellisen (2007)
p63 and p73 in human cancer: defining the network
Oncogene, 26
S. Donzelli, F. Biagioni, F. Fausti, S. Strano, G. Fontemaggi, G. Blandino (2008)
Oncogenomic Approaches in Exploring Gain of Function of Mutant p53
Current Genomics, 9
P. Kringen, A. Bergamaschi, E. Due, Yun Wang, E. Tagliabue, J. Nesland, Aune Nehman, Neeme Tönisson, A. Børresen-Dale (2005)
Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas.
BioTechniques, 39 5
A. Sigal, Devorah Matas, N. Almog, N. Goldfinger, V. Rotter (2001)
The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis
Oncogene, 20
J. Bergh, T. Norberg, S. Sjögren, A. Lindgren, L. Holmberg (1995)
Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy
Nature Medicine, 1
Ke Lin, N. Rockliffe, G. Johnson, P. Sherrington, Andrew Pettitt (2008)
Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells
Oncogene, 27
A. Patócs, Li Zhang, Yaomin Xu, F. Weber, T. Caldés, G. Mutter, Petra Platzer, C. Eng (2007)
Breast-cancer stromal cells with TP53 mutations and nodal metastases.
The New England journal of medicine, 357 25
M. Schuijer, E. Berns (2003)
TP53 and ovarian cancer
Human Mutation, 21
Surojit Sur, R. Pagliarini, F. Bunz, C. Rago, L. Diaz, K. Kinzler, B. Vogelstein, N. Papadopoulos (2009)
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
Proceedings of the National Academy of Sciences, 106
Shih-Ching Chang, Jen‐Kou Lin, Shung-Haur Yang, Huann‐Sheng Wang, A. Li, C. Chi (2006)
Relationship between genetic alterations and prognosis in sporadic colorectal cancer
International Journal of Cancer, 118
M. Olivier, Anita Langer√∏d, P. Carrieri, J. Bergh, S. Klaar, J. Eyfjord, C. Theillet, C. Rodríguez, R. Lidereau, Ivan Bi√®che, J. Varley, Y. Bignon, N. Uhrhammer, R. Winqvist, A. Jukkola-Vuorinen, D. Niederacher, S. Kato, C. Ishioka, P. Hainaut, Anne-Lise B√∏rresen-Dale (2006)
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, 12
PW Hinds (1987)
10.1128/MCB.7.8.2863
Mol. Cell Biol., 7
M. Scian, Katherine Stagliano, M. Ellis, S. Hassan, M. Bowman, M. Miles, S. Deb, S. Deb (2004)
Modulation of Gene Expression by Tumor-Derived p53 Mutants
Cancer Research, 64
J. Kravchenko, G. Ilyinskaya, G. Ilyinskaya, Pavel Komarov, L. Agapova, D. Kochetkov, D. Kochetkov, Evguenia Strom, Elena Frolova, I. Kovriga, Andrei Gudkov, Elena Feinstein, P. Chumakov, P. Chumakov (2008)
Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway
Proceedings of the National Academy of Sciences, 105
C. Esser, M. Scheffner, J. Höhfeld (2005)
The Chaperone-associated Ubiquitin Ligase CHIP Is Able to Target p53 for Proteasomal Degradation*
Journal of Biological Chemistry, 280
G. Shaulsky, N. Goldfinger, V. Rotter (1991)
Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.
Cancer research, 51 19
M. Poeta, M. Poeta, J. Manola, Meredith Goldwasser, A. Forastiere, N. Benoit, J. Califano, J. Ridge, J. Goodwin, D. Kenady, John Saunders, W. Westra, D. Sidransky, Wayne Koch (2007)
TP53 mutations and survival in squamous-cell carcinoma of the head and neck.
The New England journal of medicine, 357 25
S. Strano, S. Dell’Orso, S. Agostino, G. Fontemaggi, A. Sacchi, G. Blandino (2007)
Mutant p53: an oncogenic transcription factor
Oncogene, 26
G. Shaulsky, N. Goldfinger, A. Ben-Ze'ev, V. Rotter (1990)
Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis
Molecular and Cellular Biology, 10
G. Balogh, D. Mailo, M. Corte, P. Roncoroni, H. Nardi, E. Vincent, D. Martinez, M. Cafasso, A. Frizza, G. Ponce, E. Barutta, P. Lizarraga, G. Lizarraga, C. Monti, E. Paolillo, R. Vincent, R. Quatroquio, C. Grimi, H. Maturi, M. Aimale, C. Spinsanti, H. Montero, J. Santiago, L. Shulman, M. Rivadulla, M. Machiavelli, G. Salum, M. Cuevas, J. Picolini, A. Gentili, R. Gentili, J. Mordoh (2006)
Mutant p53 protein in serum could be used as a molecular marker in human breast cancer.
International journal of oncology, 28 4
T. Soussi, T. Soussi (2007)
p53 alterations in human cancer: more questions than answers
Oncogene, 26
R. Brosh, V. Rotter (2010)
Transcriptional control of the proliferation cluster by the tumor suppressor p53.
Molecular bioSystems, 6 1
D. Eliyahu, A. Raz, P. Gruss, D. Givol, M. Oren (1984)
Participation of p53 cellular tumour antigen in transformation of normal embryonic cells
Nature, 312
Hong Shi, F. Calvez, M. Olivier, P. Hainaut (2007)
Patterns of TP53 Mutations in Human Cancer: Interplay Between Mutagenesis, DNA Repair and Selection
L. Parada, H. Land, R. Weinberg, D. Wolf, V. Rotter (1984)
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation
Nature, 312
S. Mizuarai, Kazunori Yamanaka, H. Kotani (2006)
Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
Cancer research, 66 12
L. Burke, D. Flieder, D. Guinee, E. Brambilla, A. Freedman, W. Bennett, Raymond Jones, A. Borkowski, N. Caporaso, M. Fleming, V. Trastek, P. Pairolero, H. Tazelaar, D. Midthun, J. Jett, L. Liotta, W. Travis, C. Harris (2005)
Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research, 11 1
M. Scian, Katherine Stagliano, D. Deb, M. Ellis, E. Carchman, Anindita Das, Kristopher Valerie, S. Deb, S. Deb (2004)
Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes
Oncogene, 23
J. Milner, E. Medcalf (1991)
Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation
Cell, 65
Y. Iwanaga, K. Jeang (2002)
Expression of mitotic spindle checkpoint protein hsMAD1 correlates with cellular proliferation and is activated by a gain-of-function p53 mutant.
Cancer research, 62 9
Yunqing Li, F. Guessous, S. Kwon, Manish Kumar, O. Ibidapo, Lauren Fuller, E. Johnson, B. Lal, I. Hussaini, Y. Bao, J. Laterra, D. Schiff, R. Abounader (2008)
PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.
Cancer research, 68 6
Roberta Luna, D. Wagner, G. Lozano (1995)
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
Nature, 378
G Shaulsky (1990)
10.1128/MCB.10.12.6565
Mol. Cell Biol., 10
J. Bush, Gang Li (2002)
Cancer chemoresistance: The relationship between p53 and multidrug transporters
International Journal of Cancer, 98
L. Weisz, Amir Zalcenstein, P. Stambolsky, Yehudit Cohen, N. Goldfinger, M. Oren, V. Rotter (2004)
Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function
Cancer Research, 64
M. Brázdová, T. Quante, L. Tögel, Korden Walter, C. Loscher, V. Tichý, L. Cincarova, W. Deppert, G. Tolstonog (2009)
Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences
Nucleic Acids Research, 37
B. Boersma, Tiffany Howe, J. Goodman, H. Yfantis, D. Lee, S. Chanock, S. Ambs (2006)
Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Journal of the National Cancer Institute, 98 13
H. Koga, W. Deppert (2000)
Identification of genomic DNA sequences bound by mutant p53 protein (Gly245→Ser) in vivo
Oncogene, 19
R. Iggo, J. Bartek, D. Lane, K. Gatter, AdrianL. Harris (1990)
Increased expression of mutant forms of p53 oncogene in primary lung cancer
The Lancet, 335
Yuh Yang, M. Lu, J. Rao, H. Wallerand, L. Cai, W. Cao, A. Pantuck, G. Dalbagni, V. Reuter, R. Figlin, A. Belldegrun, C. Cordon-Cardo, Z. Zhang (2006)
Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis
British Journal of Cancer, 95
J. Bartek, J. Bártková, B. Vojtesek, Z. Stašková, J. Lukas, A. Rejthar, Jan Kovařík, C. Midgley, J. Gannon, D. Lane (1991)
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.
Oncogene, 6 9
Wensheng Yan, Xinbin Chen (2009)
Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function*
Journal of Biological Chemistry, 284
U. Preuss, R. Kreutzfeld, K. Scheidtmann (2000)
Tumor‐derived p53 mutant C174Y is a gain‐of‐function mutant which activates the fos promoter and enhances colony formation
International Journal of Cancer, 88
N. Tõnisson, J. Zernant, A. Kurg, Hendrik Pavel, G. Slavin, H. Roomere, Aune Meiel, P. Hainaut, A. Metspalu (2002)
Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene
Proceedings of the National Academy of Sciences of the United States of America, 99
D. Wolf, N. Harris, V. Rotter (1984)
Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene
Cell, 38
T. Soussi (2007)
Analysis of p53 Gene Alterations in Cancer: A Critical View
Silvia Agostino, G. Cortese, O. Monti, S. Dell’Orso, A. Sacchi, M. Eisenstein, G. Citro, S. Strano, G. Blandino (2008)
The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs
Cell Cycle, 7
C. Gaiddon, M. Lokshin, Jinwoo Ahn, Tingting Zhang, C. Prives (2001)
A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain
Molecular and Cellular Biology, 21
E. Kim, W. Deppert (2006)
The versatile interactions of p53 with DNA: when flexibility serves specificity
Cell Death and Differentiation, 13
V. Rotter (1983)
p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells.
Proceedings of the National Academy of Sciences of the United States of America, 80 9
P. Hainaut, K. Wiman (2005)
25 years of p53 research
L. Whitesell, P. Sutphin, Elizabeth Pulcini, Jesse Martinez, Paul Cook (1998)
The Physical Association of Multiple Molecular Chaperone Proteins with Mutant p53 Is Altered by Geldanamycin, an hsp90-Binding Agent
Molecular and Cellular Biology, 18
H. Blons, P. Laurent-Puig (2003)
TP53 and head and neck neoplasms
Human Mutation, 21
N Harris (1986)
10.1128/MCB.6.12.4650
Mol. Cell Biol., 6
A. Ventura, T. Jacks (2009)
MicroRNAs and Cancer: Short RNAs Go a Long Way
Cell, 136
K. Kurose, K. Gilley, S. Matsumoto, P. Watson, Xiao-ping Zhou, C. Eng (2002)
Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas
Nature Genetics, 32
C. Tepper, J. Gregg, Xubao Shi, R. Vinall, Colin Baron, Philip Ryan, P. Desprez, H. Kung, R. White (2005)
Profiling of gene expression changes caused by p53 gain‐of‐function mutant alleles in prostate cancer cells
The Prostate, 65
SJ Done (2001)
10.1093/jnci/93.9.700
J. Natl Cancer Inst., 93
IG Campbell (2008)
10.1056/NEJMc086024
N. Engl. J. Med., 358
Tamara Terzian, Young-Ah Suh, T. Iwakuma, S. Post, Manja Neumann, G. Lang, C. Pelt, G. Lozano (2008)
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.
Genes & development, 22 10
P. Hinds, C. Finlay, A. Frey, Arnold Levine (1987)
Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines
Molecular and Cellular Biology, 7
M. Maiuri, E. Tasdemir, E. Tasdemir, A. Criollo, A. Criollo, E. Morselli, E. Morselli, J. Vicencio, J. Vicencio, R. Carnuccio, G. Kroemer, G. Kroemer (2009)
Control of autophagy by oncogenes and tumor suppressor genes
Cell Death and Differentiation, 16
N. Harris, E. Brill, O. Shohat, M. Prokocimer, D. Wolf, N. Arai, V. Rotter (1986)
Molecular basis for heterogeneity of the human p53 protein
Molecular and Cellular Biology, 6
L. Weisz, A. Damalas, M. Liontos, Panagiotis Karakaidos, G. Fontemaggi, Revital Maor-Aloni, M. Kalis, M. Levrero, S. Strano, V. Gorgoulis, V. Rotter, G. Blandino, M. Oren (2007)
Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells.
Cancer research, 67 6
L. Lavra, Alessandra Ulivieri, C. Rinaldo, R. Dominici, M. Volante, Emidio Luciani, A. Bartolazzi, F. Frasca, S. Soddu, S. Sciacchitano (2009)
Gal‐3 is stimulated by gain‐of‐function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas
The Journal of Pathology, 218
G. Bossi, F. Marampon, Revital Maor-Aloni, B. Zani, V. Rotter, M. Oren, S. Strano, G. Blandino, A. Sacchi (2008)
Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy
Cell Cycle, 7
Shih-Ching Chang, Jen‐Kou Lin, Tzu-chen Lin, W. Liang (2005)
Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
International journal of oncology, 26 1
C. Whibley, P. Pharoah, M. Hollstein (2009)
p53 polymorphisms: cancer implications
Nature Reviews Cancer, 9
P. Keohavong, Weimin Gao, Hussam Mady, A. Kanbour‐Shakir, M. Melhem (2004)
Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
Cancer letters, 212 1
Hoseok Song, M. Hollstein, Yang Xu (2007)
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
Nature Cell Biology, 9
Runzhao Li, P. Sutphin, D. Schwartz, Devorah Matas, N. Almog, R. Wolkowicz, N. Goldfinger, H. Pei, M. Prokocimer, V. Rotter (1998)
Mutant p53 protein expression interferes with p53-independent apoptotic pathways
Oncogene, 16
S. Jones, A. Roe, L. Donehower, A. Bradley (1995)
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Nature, 378
Y. Haupt, R. Maya, A. Kazaz, M. Oren (1997)
Mdm2 promotes the rapid degradation of p53
Nature, 387
T. Ecke, M. Sachs, S. Lenk, S. Loening, H. Schlechte (2008)
TP53 gene mutations as an independent marker for urinary bladder cancer progression.
International journal of molecular medicine, 21 5
A. Petitjean, M. Achatz, A. Børresen-Dale, P. Hainaut, M. Olivier (2007)
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes
Oncogene, 26
U. Kelavkar, K. Badr (1999)
Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene.
Proceedings of the National Academy of Sciences of the United States of America, 96 8
Petr Müller, Roman Hrstka, D. Coomber, David Lane, B. Vojtesek (2008)
Chaperone-dependent stabilization and degradation of p53 mutants
Oncogene, 27
D. Molleví, T. Serrano, M. Ginesta, J. Valls, J. Torras, M. Navarro, E. Ramos, J. Germà, E. Jaurrieta, V. Moreno, J. Figueras, G. Capellá, A. Villanueva (2007)
Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection.
Carcinogenesis, 28 6
X Ma (2008)
10.1093/annonc/mdn503
Ann. Oncol. Abstr., 19
Silvia Agostino, S. Strano, Velia Emiliozzi, V. Zerbini, M. Mottolese, A. Sacchi, G. Blandino, G. Piaggio (2006)
Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation.
Cancer cell, 10 3
N. Khromova, P. Kopnin, E. Stepanova, L. Agapova, B. Kopnin (2009)
p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway.
Cancer letters, 276 2
G. Zalcman, E. Bergot, P. Hainaut (2008)
Breast-cancer stromal cells with TP53 mutations.
The New England journal of medicine, 358 15
A. Petitjean, E. Mathé, S. Kato, C. Ishioka, S. Tavtigian, P. Hainaut, M. Olivier (2007)
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
Human Mutation, 28
L. Dearth, Hua Qian, Ting Wang, T. Baroni, Jue Zeng, Stephanie Chen, S. Yi, R. Brachmann (2007)
Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.
Carcinogenesis, 28 2
D. Linzer, A. Levine (1979)
Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
Cell, 17
Y. Wang, G. Kristensen, A. Børresen-Dale, Å. Helland (2007)
TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology, 18 5
M. Scian, Katherine Stagliano, M. Anderson, S. Hassan, M. Bowman, M. Miles, S. Deb, S. Deb (2005)
Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression
Molecular and Cellular Biology, 25
F. Li, J. Fraumeni (1969)
Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?
Annals of internal medicine, 71 4
B. Sepehrnia, I. Paz, G. Dasgupta, J. Momand (1996)
Heat Shock Protein 84 Forms a Complex with Mutant p53 Protein Predominantly within a Cytoplasmic Compartment of the Cell*
The Journal of Biological Chemistry, 271
D. Dittmer, Sibani Pati, G. Zambetti, Shelley Chu, A. Teresky, M. Moore, C. Finlay, A. Levine (1993)
Gain of function mutations in p53
Nature Genetics, 4
T Sjoblom (2006)
10.1126/science.1133427
Science, 314
Y. Ruano, T. Ribalta, Ángel Lope, Y. Campos-Martín, C. Fiaño, Elisa Pérez-Magán, J. Hernández-Moneo, M. Mollejo, B. Meléndez (2009)
Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
American journal of clinical pathology, 131 2
M. Frazier, Xiaoping He, Jinling Wang, Z. Gu, J. Cleveland, G. Zambetti (1998)
Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain
Molecular and Cellular Biology, 18
A. Langerød, Hongjuan Zhao, Ørnulf Borgan, J. Nesland, I. Bukholm, T. Ikdahl, R. Kåresen, A. Børresen-Dale, S. Jeffrey (2007)
TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer
Breast Cancer Research, 9
N. Sakuragi, H. Watari, Y. Ebina, R. Yamamoto, E. Steiner, H. Koelbl, M. Yano, M. Tada, T. Moriuchi (2005)
Functional analysis of p53 gene and the prognostic impact of dominant‐negative p53 mutation in endometrial cancer
International Journal of Cancer, 116
C. Sotiriou, L. Pusztai (2009)
Gene-expression signatures in breast cancer.
The New England journal of medicine, 360 8
Ella Kim, W. Deppert (2004)
Transcriptional activities of mutant p53: When mutations are more than a loss
Journal of Cellular Biochemistry, 93
Y. Tabach, M. Milyavsky, I. Shats, R. Brosh, O. Zuk, Assif Yitzhaky, Roberto Mantovani, E. Domany, Varda Rotter, Y. Pilpel (2005)
The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation
Molecular Systems Biology, 1
Kristine Kleivi, C. Diep, N. Pandis, S. Heim, M. Teixeira, R. Lothe (2005)
TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas
The Journal of Pathology, 207
Wenge Wang, W. El-Deiry (2008)
Restoration of p53 to limit tumor growth
Current Opinion in Oncology, 20
S. Peller, V. Rotter (2003)
TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance
Human Mutation, 21
N. Reich, A. Levine (1984)
Growth regulation of a cellular tumour antigen, p53, in nontransformed cells
Nature, 308
L Burke (2005)
10.1158/1078-0432.232.11.1
Clin. Cancer Res., 11
A. Salinas-Sánchez, J. Lorenzo-Romero, J. Giménez-Bachs, F. Sánchez-Sánchez, M. Donate-Moreno, Antonio Rubio-Del-Campo, I. Hernández-Millán, M. Segura-Martín, M. Atiénzar-Tobarra, Julio Escribano-Martínez (2008)
Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
Urologic oncology, 26 6
M. Troester, Jason Herschkowitz, D. Oh, Xiaping He, K. Hoadley, C. Barbier, C. Perou (2006)
Gene expression patterns associated with p53 status in breast cancer
BMC Cancer, 6
M. Olivier, P. Hainaut, A. Børresen-Dale (2007)
Prognostic and Predictive Value of TP53 Mutations in Human Cancer
Jianmin Zhang, C. Pickering, Charles Holst, M. Gauthier, T. Tlsty (2006)
p16INK4a modulates p53 in primary human mammary epithelial cells.
Cancer research, 66 21
Mikhail Blagosklonny, J. Toretsky, Sean Bohen, Len Neckers (1996)
Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
Proceedings of the National Academy of Sciences of the United States of America, 93 16
Devorah Matas, A. Sigal, P. Stambolsky, M. Milyavsky, L. Weisz, D. Schwartz, N. Goldfinger, V. Rotter (2001)
Integrity of the N‐terminal transcription domain of p53 is required for mutant p53 interference with drug‐induced apoptosis
The EMBO Journal, 20
Seung Dong, G. Traverso, Constance Johnson, L. Geng, R. Favis, K. Boynton, K. Hibi, S. Goodman, M. D'Allessio, P. Paty, S. Hamilton, D. Sidransky, F. Barany, B. Levin, A. Shuber, K. Kinzler, B. Vogelstein, Jin Jen (2001)
Detecting colorectal cancer in stool with the use of multiple genetic targets.
Journal of the National Cancer Institute, 93 11
F. Li, J. Fraumeni (1969)
Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome.
Journal of the National Cancer Institute, 43
Imad Ahmed, Seamus Kelly, John Anderson, Brian Angus, C. Challen, John Lunec (2008)
The predictive value of p53 and p33ING1b in patients with Dukes'C colorectal cancer
Colorectal Disease, 10
(2005)
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.
Proceedings of the National Academy of Sciences of the United States of America, 102 38
D. Malkin, F. Li, L. Strong, J. Fraumeni, C. Nelson, D. Kim, J. Kassel, M. Gryka, F. Bischoff, M. Tainsky (1990)
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.
Science, 250 4985
E. Morselli, E. Tasdemir, M. Maiuri, L. Galluzzi, O. Kepp, A. Criollo, J. Vicencio, T. Soussi, G. Kroemer (2008)
Mutant p53 protein localized in the cytoplasm inhibits autophagy
Cell Cycle, 7
K. Olive, D. Tuveson, Zachary Ruhe, Bob Yin, Nicholas Willis, R. Bronson, D. Crowley, T. Jacks (2004)
Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome
Cell, 119
Amir Zalcenstein, P. Stambolsky, L. Weisz, Martina Müller, D. Wallach, T. Goncharov, P. Krammer, V. Rotter, M. Oren (2003)
Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants
Oncogene, 22
Eyal Kalo, Y. Buganim, Keren Shapira, Hilla Besserglick, N. Goldfinger, L. Weisz, P. Stambolsky, Y. Henis, V. Rotter (2007)
Mutant p53 Attenuates the SMAD-Dependent Transforming Growth Factor β1 (TGF-β1) Signaling Pathway by Repressing the Expression of TGF-β Receptor Type II
Molecular and Cellular Biology, 27
G. Bougeard, R. Sesboüé, S. Desurmont, P. Berthet, V. Bonadona, B. Buecher, O. Caron, C. Colas, M. Collonge-Rame, Capucine Delnatte, C. Dugast, J. Fricker, M. Gauthier‐Villars, P. Gesta, P. Jonveaux, C. Lasset, B. Leheup, M. Longy, C. Nogué (2008)
Molecular basis of the Li–Fraumeni syndrome: an update from the French LFS families
Journal of Medical Genetics, 45
S. Kato, Shuang-yin Han, Wen Liu, Kazunori Otsuka, H. Shibata, R. Kanamaru, C. Ishioka (2003)
Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis
Proceedings of the National Academy of Sciences of the United States of America, 100
Y. Li, C. Prives (2007)
Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?
Oncogene, 26
F. Vikhanskaya, Ming Lee, Marco Mazzoletti, M. Broggini, K. Sabapathy (2007)
Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53
Nucleic Acids Research, 35
V. Rotter, M. Boss, D. Baltimore (1981)
Increased concentration of an apparently identical cellular protein in cells transformed by either Abelson murine leukemia virus or other transforming agents
Journal of Virology, 38
O. Suad, H. Rozenberg, R. Brosh, Y. Diskin‐Posner, N. Kessler, L. Shimon, F. Frolow, Atar Liran, V. Rotter, Z. Shakked (2009)
Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Journal of molecular biology, 385 1
C. Midgley, D. Lane (1997)
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding
Oncogene, 15
L. Trotman, P. Pandolfi (2003)
PTEN and p53: who will get the upper hand?
Cancer cell, 3 2
SJ Done, S Eskandarian, S Bull, M Redston, IL Andrulis (2001)
p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast
J. Natl Cancer Inst., 93
Xiaolong Yang, A. Pater, Shou-Ching Tang (1999)
Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants
Oncogene, 18
M. Irwin (2004)
Family Feud in Chemosensitvity: p73 and Mutant p53
Cell Cycle, 3
G. Blandino, A. Levine, M. Oren (1999)
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
Oncogene, 18
M. Oren (2003)
Decision making by p53: life, death and cancer
Cell Death and Differentiation, 10
A. Joerger, A. Fersht (2007)
Structure–function–rescue: the diverse nature of common p53 cancer mutants
Oncogene, 26
V. Rotter, H. Abutbul, A. Ben-Ze'ev (1983)
P53 transformation‐related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non‐transformed fibroblasts.
The EMBO Journal, 2
Loging Wt, D. Reisman (1999)
Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 8 11
Sachin Kumar, A. Mohan, R. Guleria (2009)
Prognostic implications of circulating anti-p53 antibodies in lung cancer--a review.
European journal of cancer care, 18 3
T. Soussi, C. Béroud (2001)
Assessing TP53 status in human tumours to evaluate clinical outcome
Nature Reviews Cancer, 1
Y. Buganim, Eyal Kalo, R. Brosh, Hila Besserglick, I. Nachmany, Y. Rais, P. Stambolsky, Xiaohu Tang, M. Milyavsky, I. Shats, M. Kalis, N. Goldfinger, V. Rotter (2006)
Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction.
Cancer research, 66 22
G. Lang, T. Iwakuma, Young-Ah Suh, Geng-Hung Liu, Vasundhara Rao, J. Parant, Y. Valentin-Vega, Tamara Terzian, L. Caldwell, L. Strong, A. El-Naggar, G. Lozano (2004)
Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome
Cell, 119
LD Miller (2005)
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl Acad. Sci. U S
A, 102
W. Schulze, Lei Deng, M. Mann (2005)
Phosphotyrosine interactome of the ErbB-receptor kinase family
Molecular Systems Biology, 1
S. Deb, C. Jackson, M. Subler, D. Martin (1992)
Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells
Journal of Virology, 66
M. Sánchez-Carbayo, N. Socci, L. Richstone, M. Cortón, N. Behrendt, Julia Wulkfuhle, B. Bochner, E. Petricoin, C. Cordon-Cardo (2007)
Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression.
The American journal of pathology, 171 5
R. Brosh, Reut Shalgi, Atar Liran, G. Landan, K. Korotayev, G. Nguyen, E. Enerly, H. Johnsen, Y. Buganim, H. Solomon, I. Goldstein, Shalom Madar, N. Goldfinger, A. Børresen-Dale, D. Ginsberg, C. Harris, Y. Pilpel, M. Oren, V. Rotter (2008)
p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation
Molecular Systems Biology, 4
M. Kress, E. May, R. Cassingena, P. May (1979)
Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum
Journal of Virology, 31
T. Batchelor, R. Betensky, J. Esposito, L. Pham, M. Dorfman, N. Piscatelli, S. Jhung, David Rhee, D. Louis (2004)
Age-Dependent Prognostic Effects of Genetic Alterations in Glioblastoma
Clinical Cancer Research, 10
E. Pugacheva, A. Ivanov, J. Kravchenko, B. Kopnin, A. Levine, P. Chumakov (2002)
Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil
Oncogene, 21
J. Birch, V. Blair, A. Kelsey, D. Evans, M. Harris, K. Tricker, J. Varley (1998)
Cancer phenotype correlates with constitutional TP53 genotype in families with the Li–Fraumeni syndrome
Oncogene, 17
T. Aas, A. Børresen, S. Geisler, B. Smith-Sørensen, H. Johnsen, J. Varhaug, L. Akslen, P. Lønning (1996)
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
Nature Medicine, 2
A. Bullock, A. Fersht (2001)
Rescuing the function of mutant p53
Nature Reviews Cancer, 1
P. Monti, Y. Ciribilli, J. Jordan, P. Menichini, D. Umbach, M. Resnick, L. Luzzatto, A. Inga, G. Fronza (2007)
Transcriptional Functionality of Germ Line p53 Mutants Influences Cancer Phenotype
Clinical Cancer Research, 13
A. Deleo, G. Jay, E. Appella, G. Dubois, L. Law, L. Old (1979)
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.
Proceedings of the National Academy of Sciences of the United States of America, 76 5
Young Lee, Sook Lee, G. Das, U. Park, S. Park, Yoonik Lee (2000)
Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma
Oncogene, 19
M. Whitfield, Lacy George, Gavin Grant, C. Perou (2006)
Common markers of proliferation
Nature Reviews Cancer, 6
E. Flores, Shomit Sengupta, John Miller, J. Newman, R. Bronson, D. Crowley, A. Yang, F. McKeon, T. Jacks (2005)
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family.
Cancer cell, 7 4
S. Bull, H. Ozçelik, Dushanthi Pinnaduwage, M. Blackstein, D. Sutherland, K. Pritchard, A. Tzontcheva, S. Sidlofsky, W. Hanna, A. Qizilbash, M. Tweeddale, S. Fine, D. McCready, I. Andrulis (2004)
The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 1

Publisher: Springer Journals
Copyright: Copyright © 2009 by Nature Publishing Group
Subject: Biomedicine; Biomedicine, general; Cancer Research
ISSN: 1474-175X
eISSN: 1474-1768
DOI: 10.1038/nrc2693
Publisher site: See Article on Publisher Site

Abstract

Mutant p53 proteins not only lose their tumour suppressive ability, but also gain new properties that promote tumorigenesis. What are these properties and what are the clinical implications?

Journal

Nature Reviews Cancer – Springer Journals

Published: Aug 20, 2009

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

When mutants gain new powers: news from the mutant p53 field

When mutants gain new powers: news from the mutant p53 field

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

When mutants gain new powers: news from the mutant p53 field

When mutants gain new powers: news from the mutant p53 field

References (202)

Abstract

Journal

Recommended Articles

There are no references for this article.

Our policy towards the use of cookies